secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-042967
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive reports Q1 net income $0.5M, cash $19.8M, OLC PDUFA June 28, 2025
---------------------------------------------------------------------------

- Net income attributable to common stockholders of $0.5M for Q1 2025, vs net loss of $21.2M in Q1 2024.
- Cash and cash equivalents totaled $19.8M as of March 31, 2025.
- OLC NDA under FDA review with PDUFA target action date of June 28, 2025; commercial launch preparation ongoing.
- R&D expenses fell to $2.2M from $6.8M; G&A rose to $5.8M from $2.4M due to launch prep costs.
- Patient survey data presented at NKF and ANNA meetings identified pill burden as primary adherence barrier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/0001213900-25-042967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea0242081-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer